Silverfin false false 30/04/2025 16/04/2024 30/04/2025 P Waring 16/04/2024 05 September 2025 The company was incorporated on 16 April 2024 and commenced trading on the same day. The principal activity of the company is that of providing research and experimental development on biotechnology and specialists medical practice activities. 15650580 2025-04-30 15650580 bus:Director1 2025-04-30 15650580 core:CurrentFinancialInstruments 2025-04-30 15650580 core:ShareCapital 2025-04-30 15650580 core:RetainedEarningsAccumulatedLosses 2025-04-30 15650580 core:ComputerEquipment 2024-04-15 15650580 2024-04-15 15650580 core:ComputerEquipment 2025-04-30 15650580 core:CostValuation 2024-04-15 15650580 core:AdditionsToInvestments 2025-04-30 15650580 core:CostValuation 2025-04-30 15650580 bus:OrdinaryShareClass1 2025-04-30 15650580 2024-04-16 2025-04-30 15650580 bus:FilletedAccounts 2024-04-16 2025-04-30 15650580 bus:SmallEntities 2024-04-16 2025-04-30 15650580 bus:AuditExempt-NoAccountantsReport 2024-04-16 2025-04-30 15650580 bus:PrivateLimitedCompanyLtd 2024-04-16 2025-04-30 15650580 bus:Director1 2024-04-16 2025-04-30 15650580 core:ComputerEquipment core:TopRangeValue 2024-04-16 2025-04-30 15650580 core:ComputerEquipment 2024-04-16 2025-04-30 15650580 bus:OrdinaryShareClass1 2024-04-16 2025-04-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 15650580 (England and Wales)

TRANSLATIONAL PATHOLOGY CONSULTING SERVICES LIMITED

Unaudited Financial Statements
For the financial period from 16 April 2024 to 30 April 2025
Pages for filing with the registrar

TRANSLATIONAL PATHOLOGY CONSULTING SERVICES LIMITED

Unaudited Financial Statements

For the financial period from 16 April 2024 to 30 April 2025

Contents

TRANSLATIONAL PATHOLOGY CONSULTING SERVICES LIMITED

BALANCE SHEET

As at 30 April 2025
TRANSLATIONAL PATHOLOGY CONSULTING SERVICES LIMITED

BALANCE SHEET (continued)

As at 30 April 2025
Note 30.04.2025
£
Fixed assets
Tangible assets 3 1,988
Investments 4 31,345
33,333
Current assets
Cash at bank and in hand 835
835
Creditors: amounts falling due within one year 5 ( 8,693)
Net current liabilities (7,858)
Total assets less current liabilities 25,475
Provision for liabilities ( 497)
Net assets 24,978
Capital and reserves
Called-up share capital 6 1
Profit and loss account 24,977
Total shareholder's funds 24,978

For the financial period ending 30 April 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Translational Pathology Consulting Services Limited (registered number: 15650580) were approved and authorised for issue by the Director on 05 September 2025. They were signed on its behalf by:

P Waring
Director
TRANSLATIONAL PATHOLOGY CONSULTING SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 16 April 2024 to 30 April 2025
TRANSLATIONAL PATHOLOGY CONSULTING SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial period from 16 April 2024 to 30 April 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Translational Pathology Consulting Services Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Aldgate Tower, 2 Leman Street, London, E1W 9US, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Reporting period length

The director has elected to prepare these financial statements, which represent the company’s first set of accounts, for a 12 month 15 day period beginning from the date of incorporation of the company on 16 April 2024.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the Balance Sheet date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the Balance Sheet date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Computer equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss.

If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

2. Employees

Period from
16.04.2024 to
30.04.2025
Number
Monthly average number of persons employed by the Company during the period, including the director 1

3. Tangible assets

Computer equipment Total
£ £
Cost
At 16 April 2024 0 0
Additions 2,982 2,982
At 30 April 2025 2,982 2,982
Accumulated depreciation
At 16 April 2024 0 0
Charge for the financial period 994 994
At 30 April 2025 994 994
Net book value
At 30 April 2025 1,988 1,988

4. Fixed asset investments

Other investments Total
£ £
Cost or valuation before impairment
At 16 April 2024 0 0
Additions 31,345 31,345
At 30 April 2025 31,345 31,345
Carrying value at 30 April 2025 31,345 31,345

5. Creditors: amounts falling due within one year

30.04.2025
£
Amounts owed to director 356
Accruals 2,400
Taxation and social security 5,937
8,693

6. Called-up share capital

30.04.2025
£
Allotted, called-up and fully-paid
1 Ordinary share of £ 1.00 1

On 16 April 2024, the day of incorporation, 1 Ordinary shares of £1 each were issued and fully paid.

7. Related party transactions

At the year end, the company owed £355 to P Waring, the director of the company, in respect of an interest free loan which is repayable on demand.